The single cell transcriptomic landscape of recurrent giant cell tumor of bone following neoadjuvant denosumab therapy

Xianglin Hu; Huajian Wu; Biqiang Zheng; Chao Liang; Bochong Shi; Qingrong Ye; Shuoer Wang; Weiluo Cai; Tu Hu; Yong Chen; Mo Cheng; Wangjun Yan; Wending Huang

doi:10.1016/j.jgg.2026.03.001

The single cell transcriptomic landscape of recurrent giant cell tumor of bone following neoadjuvant denosumab therapy

doi: 10.1016/j.jgg.2026.03.001

Xianglin Hu^a,b,
Huajian Wu^c,
Biqiang Zheng^a,b,
Chao Liang^a,b,
Bochong Shi^a,b,
Qingrong Ye^a,b,
Shuoer Wang^a,b,
Weiluo Cai^a,b,
Tu Hu^a,b,
Yong Chen^a,b,
Mo Cheng^a,b,
Wangjun Yan^a,b, ,,
Wending Huang^a,b, ,

a. Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China;
b. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China;
c. Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center Xiamen Hospital, Xiamen, Fujian 361027, China

基金项目:

The authors express sincere thanks to OE Biotech Co., Ltd. (Shanghai, China) for providing single-cell RNA-seq. This study was supported by the National Natural Science Foundation of China (81872179).

详细信息

通讯作者:
Wangjun Yan,E-mail:yanwj@fudan.edu.cn

Wending Huang,E-mail:orienthwd@163.com

计量
- 文章访问数: 23
- HTML全文浏览量: 12
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2024-10-06
- 录用日期: 2026-03-02
- 修回日期: 2026-02-28
- 网络出版日期: 2026-03-06

The single cell transcriptomic landscape of recurrent giant cell tumor of bone following neoadjuvant denosumab therapy

Xianglin Hu^a,b,
Huajian Wu^c,
Biqiang Zheng^a,b,
Chao Liang^a,b,
Bochong Shi^a,b,
Qingrong Ye^a,b,
Shuoer Wang^a,b,
Weiluo Cai^a,b,
Tu Hu^a,b,
Yong Chen^a,b,
Mo Cheng^a,b,
Wangjun Yan^{a,b
, ,},
Wending Huang^{a,b
, ,}

a. Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China;
b. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China;
c. Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center Xiamen Hospital, Xiamen, Fujian 361027, China

Funds:

摘要

摘要: Denosumab (DMAb) is widely used as a neoadjuvant therapy to downstage giant cell tumor of bone (GCTB). However, increasing evidence demonstrates that neoadjuvant DMAb may increase the local recurrence (LR) risk following curettage of GCTB. It remains unclear about the potential mechanisms for neoadjuvant DMAb-associated LR of GCTB. Here, we perform single-cell RNA sequencing on untreated primary GCTB, neoadjuvant DMAb-treated primary GCTB, and relapsed GCTB following discontinuation of DMAb after curettage. A total of 33,440 cells are obtained. Osteoclast-like giant cells nearly disappear in primary GCTB after neoadjuvant DMAb treatment, but rebound following DMAb discontinuation in recurrent GCTB. Neoadjuvant DMAb therapy induces the transformation of TNFSF11 (RANKL)-positive neoplastic cells into SPP1 (osteopontin)-positive and CA2-positive neoplastic cells. Neoadjuvant DMAb therapy induces a durable intratumoral immunosuppressive environment, characterized by an increased frequency of regulatory T cells (Tregs) and decreased levels of cytotoxic CD8⁺ T cells and natural killer T (NKT) cells. In addition, DMAb-induced differentiation of monocytes to Trem2⁺ macrophages provides a favorable microenvironment that facilitates tumor relapse. CSF1R inhibitor can inhibit the tumor growth of recurrent GCTB. Targeting CSF1R and alleviating T cell exhaustion may provide therapeutic insights for the management of relapsed GCTB following DMAb discontinuation.
- Denosumab /
- Giant cell tumor of bone /
- Curettage /
- Local recurrence /
- Single-cell RNA sequencing /
- Receptor activator of nuclear factor kappa-B ligand
Abstract: Denosumab (DMAb) is widely used as a neoadjuvant therapy to downstage giant cell tumor of bone (GCTB). However, increasing evidence demonstrates that neoadjuvant DMAb may increase the local recurrence (LR) risk following curettage of GCTB. It remains unclear about the potential mechanisms for neoadjuvant DMAb-associated LR of GCTB. Here, we perform single-cell RNA sequencing on untreated primary GCTB, neoadjuvant DMAb-treated primary GCTB, and relapsed GCTB following discontinuation of DMAb after curettage. A total of 33,440 cells are obtained. Osteoclast-like giant cells nearly disappear in primary GCTB after neoadjuvant DMAb treatment, but rebound following DMAb discontinuation in recurrent GCTB. Neoadjuvant DMAb therapy induces the transformation of TNFSF11 (RANKL)-positive neoplastic cells into SPP1 (osteopontin)-positive and CA2-positive neoplastic cells. Neoadjuvant DMAb therapy induces a durable intratumoral immunosuppressive environment, characterized by an increased frequency of regulatory T cells (Tregs) and decreased levels of cytotoxic CD8⁺ T cells and natural killer T (NKT) cells. In addition, DMAb-induced differentiation of monocytes to Trem2⁺ macrophages provides a favorable microenvironment that facilitates tumor relapse. CSF1R inhibitor can inhibit the tumor growth of recurrent GCTB. Targeting CSF1R and alleviating T cell exhaustion may provide therapeutic insights for the management of relapsed GCTB following DMAb discontinuation.
- Denosumab /
- Giant cell tumor of bone /
- Curettage /
- Local recurrence /
- Single-cell RNA sequencing /
- Receptor activator of nuclear factor kappa-B ligand

HTML全文

参考文献(61)

Agrawal, A.C., Saini, D.,Nanda, R., 2024. Serum osteopontin as a potential marker for metastasis and prognosis in primary osteogenic sarcoma: A systematic review. Cureus 16, e60544.

Aibar, S., Gonzalez-Blas, C.B., Moerman, T., Huynh-Thu, V.A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.C., Geurts, P., Aerts, J., et al., 2017. SCENIC: Single-cell regulatory network inference and clustering. Nat. Methods 14, 1083-1086.

Alaqaili, S.I., Abduljabbar, A.M., Altaho, A.J., Khan, A.A.,Alherabi, J.A., 2018. Malignant sarcomatous transformation of benign giant cell tumor of bone after treatment with denosumab therapy: A literature review of reported cases. Cureus 10, e3792.

Aran, D., Looney, A.P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R.P., Wolters, P.J., Abate, A.R., et al., 2019. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163-172.

Asano, N., Saito, M., Kobayashi, E., Morii, T., Kikuta, K., Watanabe, I., Anazawa, U., Takeuchi, K., Suzuki, Y., Susa, M., et al., 2022. Preoperative denosumab therapy against giant cell tumor of bone is associated with an increased risk of local recurrence after curettage surgery. Ann. Surg. Oncol. 29, 3992-4000.

Bache, M., Kappler, M., Wichmann, H., Rot, S., Hahnel, A., Greither, T., Said, H.M., Kotzsch, M., Wurl, P., Taubert, H., et al., 2010. Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer 10, 132.

Binnewies, M., Pollack, J.L., Rudolph, J., Dash, S., Abushawish, M., Lee, T., Jahchan, N.S., Canaday, P., Lu, E., Norng, M., et al., 2021. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 37, 109844.

Borkowska, A.M., Szumera-Cieckiewicz, A., Szostakowski, B., Pienkowski, A.,Rutkowski, P.L., 2022. Denosumab in giant cell tumor of bone: Multidisciplinary medical management based on pathophysiological mechanisms and real-world evidence. Cancers (Basel) 14, 2290.

Butler, A., Hoffman, P., Smibert, P., Papalexi, E.,Satija, R., 2018. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411-420.

Cannarile, M.A., Weisser, M., Jacob, W., Jegg, A.M., Ries, C.H.,Ruttinger, D., 2017. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. ImmunoTher. Cancer 5, 53.

Castello, L.M., Raineri, D., Salmi, L., Clemente, N., Vaschetto, R., Quaglia, M., Garzaro, M., Gentilli, S., Navalesi, P., Cantaluppi, V., et al., 2017. Osteopontin at the crossroads of inflammation and tumor progression. Mediators Inflamm. 2017, 4049098.

Chawla, S., Blay, J.Y., Rutkowski, P., Le Cesne, A., Reichardt, P., Gelderblom, H., Grimer, R.J., Choy, E., Skubitz, K., Seeger, L., et al., 2019. Denosumab in patients with giant-cell tumour of bone: A multicentre, open-label, phase 2 study. Lancet Oncol. 20, 1719-1729.

Chinder, P.S., Hindiskere, S., Doddarangappa, S.,Pal, U., 2019. Evaluation of local recurrence in giant-cell tumor of bone treated by neoadjuvant denosumab. Clin Orthop Surg 11, 352-360.

De Leon-Oliva, D., Barrena-Blazquez, S., Jimenez-Alvarez, L., Fraile-Martinez, O., Garcia-Montero, C., Lopez-Gonzalez, L., Torres-Carranza, D., Garcia-Puente, L.M., Carranza, S.T., Alvarez-Mon, M., et al., 2023. The RANK-RANKL-OPG system: A multifaceted regulator of homeostasis, immunity, and cancer. Medicina (Kaunas) 59, 1752.

Errani, C., Tsukamoto, S., Leone, G., Righi, A., Akahane, M., Tanaka, Y.,Donati, D.M., 2018. Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. J. Bone Joint Surg. Am. 100, 496-504.

Feng, W., He, M., Jiang, X., Liu, H., Xie, T., Qin, Z., Huang, Q., Liao, S., Lin, C., He, J., et al., 2021. Single-cell RNA sequencing reveals the migration of osteoclasts in giant cell tumor of bone. Front. Oncol. 11, 715552.

Fujiwara, T., Yakoub, M.A., Chandler, A., Christ, A.B., Yang, G., Ouerfelli, O., Rajasekhar, V.K., Yoshida, A., Kondo, H., Hata, T., et al., 2021. CSF1/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol. Cancer Ther. 20, 1388-1399.

Gao, R., Bai, S., Henderson, Y.C., Lin, Y., Schalck, A., Yan, Y., Kumar, T., Hu, M., Sei, E., Davis, A., et al., 2021. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat. Biotechnol. 39, 599-608.

Gelderblom, H.,de Sande, M.V., 2020. Pexidartinib: First approved systemic therapy for patients with tenosynovial giant cell tumor. Future Oncol. 16, 2345-2356.

Haghverdi, L., Lun, A.T.L., Morgan, M.D.,Marioni, J.C., 2018. Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat. Biotechnol. 36, 421-427.

Hu, X., Sun, Z., Huang, W., Sun, Y.,Yan, W., 2022. Real-world treatment and survival outcome of malignant giant cell tumor of bone in the pre-denosumab versus post-denosumab era. Int. J. Surg. 102, 106667.

Jin, S., Guerrero-Juarez, C.F., Zhang, L., Chang, I., Ramos, R., Kuan, C.H., Myung, P., Plikus, M.V.,Nie, Q., 2021. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088.

Johan, M.P., Paturusi, I.A., Yurianto, H., Usman, M.A., Arifin, J., Abidin, M.A., Kawilarang, M.A.,Kennedy, D., 2022. The role of neutrophil to lymphocyte ratio in predicting lung metastasis in giant cell tumor of the extremities. Eur. Rev. Med. Pharmacol. Sci. 26, 8914-8923.

Lei, Y., Tang, R., Xu, J., Wang, W., Zhang, B., Liu, J., Yu, X.,Shi, S., 2021. Applications of single-cell sequencing in cancer research: Progress and perspectives. J. Hematol. Oncol. 14, 91.

Li, B., Wang, P., Jiao, J., Wei, H., Xu, W.,Zhou, P., 2022. Roles of the RANKL-RANK axis in immunity-implications for pathogenesis and treatment of bone metastasis. Front. Immunol. 13, 824117.

Li, Y.S., Deng, Z.H., Zeng, C.,Lei, G.H., 2015. Role of osteopontin in osteosarcoma. Med. Oncol. 32, 449.

Lipplaa, A., Dijkstra, S.,Gelderblom, H., 2019. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. Curr. Opin. Oncol. 31, 329-335.

Mabbott, N.A., Baillie, J.K., Brown, H., Freeman, T.C.,Hume, D.A., 2013. An expression atlas of human primary cells: Inference of gene function from coexpression networks. BMC Genomics. 14, 632.

McGinnis, C.S., Murrow, L.M.,Gartner, Z.J., 2019. Doubletfinder: Doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329-337.e324.

Medellin, M.R., Fujiwara, T., Tillman, R.M., Jeys, L.M., Gregory, J., Stevenson, J.D., Parry, M.,Abudu, A., 2018. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture. Bone Joint J. 100-b, 1626-1632.

Merah-Mourah, F., Cohen, S.O., Charron, D., Mooney, N.,Haziot, A., 2020. Identification of novel human monocyte subsets and evidence for phenotypic groups defined by interindividual variations of expression of adhesion molecules. Sci. Rep. 10, 4397.

Molgora, M., Liu, Y.A., Colonna, M.,Cella, M., 2023. TREM2: A new player in the tumor microenvironment. Semin. Immunol. 67, 101739.

Nazarizadeh, A., Alizadeh-Fanalou, S., Hosseini, A., Mirzaei, A., Salimi, V., Keshipour, H., Safizadeh, B., Jamshidi, K., Bahrabadi, M.,Tavakoli-Yaraki, M., 2021. Evaluation of local and circulating osteopontin in malignant and benign primary bone tumors. J. Bone Oncol. 29, 100377.

Palmerini, E., Chawla, N.S., Ferrari, S., Sudan, M., Picci, P., Marchesi, E., Leopardi, M.P., Syed, I., Sankhala, K.K., Parthasarathy, P., et al., 2017. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long? Eur. J. Cancer 76, 118-124.

Park, M.D., Reyes-Torres, I., LeBerichel, J., Hamon, P., LaMarche, N.M., Hegde, S., Belabed, M., Troncoso, L., Grout, J.A., Magen, A., et al., 2023. TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. Nat. Immunol. 24, 792-801.

Parkkila, S., Lasota, J., Fletcher, J.A., Ou, W.B., Kivela, A.J., Nuorva, K., Parkkila, A.K., Ollikainen, J., Sly, W.S., Waheed, A., et al., 2010. Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod. Pathol. 23, 743-750.

Parmeggiani, A., Miceli, M., Errani, C.,Facchini, G., 2021. State of the art and new concepts in giant cell tumor of bone: Imaging features and tumor characteristics. Cancers (Basel) 13, 6298.

Puram, S.V., Tirosh, I., Parikh, A.S., Patel, A.P., Yizhak, K., Gillespie, S., Rodman, C., Luo, C.L., Mroz, E.A., Emerick, K.S., et al., 2017. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611-1624.e1624.

Raimondi, A., Simeone, N., Guzzo, M., Maniezzo, M., Collini, P., Morosi, C., Greco, F.G., Frezza, A.M., Casali, P.G.,Stacchiotti, S., 2020. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: A case series analysis and literature review. ESMO Open 5, e000663.

Rasmussen, M., Sundstrom, M., Goransson Kultima, H., Botling, J., Micke, P., Birgisson, H., Glimelius, B.,Isaksson, A., 2011. Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity. Genome Biol. 12, R108.

Ren, X., Zhang, L., Zhang, Y., Li, Z., Siemers, N.,Zhang, Z., 2021. Insights gained from single-cell analysis of immune cells in the tumor microenvironment. Annu. Rev. Immunol. 39, 583-609.

Rockberg, J., Bach, B.A., Amelio, J., Hernandez, R.K., Sobocki, P., Engellau, J., Bauer, H.C.,Liede, A., 2015. Incidence trends in the diagnosis of giant cell tumor of bone in sweden since 1958. J. Bone Joint Surg. Am. 97, 1756-1766.

Rutkowski, P., Gaston, L., Borkowska, A., Stacchiotti, S., Gelderblom, H., Baldi, G.G., Palmerini, E., Casali, P., Gronchi, A., Parry, M., et al., 2018. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - multicenter analysis outside clinical trial. Eur. J. Surg. Oncol. 44, 1384-1390.

Sano, K., Suehara, Y., Okubo, T., Sasa, K., Kurihara, T., Akaike, K., Kubota, D., Torigoe, T., Hasegawa, N., Ishii, M., et al., 2020. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone. J. Orthop. Surg. (Hong Kong) 28, 2309499020929786.

Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al., 2005. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad Sci. U. S. A. 102, 15545-15550.

Sun, Y., Wu, L., Zhong, Y., Zhou, K., Hou, Y., Wang, Z., Zhang, Z., Xie, J., Wang, C., Chen, D., et al., 2021. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell 184, 404-421.e416.

Sun, Z., Wu, Z., Zhang, L., Jia, Q., Zhou, Z.,Xiao, J., 2023. Association between preoperative denosumab and the risk of local recurrence in patients with giant cell tumor of bone: A meta-analysis and systematic review. J. Cancer Res. Ther. 19, 25-33.

Suo, S., Zhu, Q., Saadatpour, A., Fei, L., Guo, G.,Yuan, G.C., 2018. Revealing the critical regulators of cell identity in the mouse cell atlas. Cell Rep. 25, 1436-1445.e1433.

Tan, X., Zhang, Y., Wei, D., Yang, Y.,Xiang, F., 2023. Denosumab for giant cell tumors of bone from 2010 to 2022: A bibliometric analysis. Clin. Exp. Med. 23, 3053-3075.

Trapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lennon, N.J., Livak, K.J., Mikkelsen, T.S.,Rinn, J.L., 2014. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381-386.

Tsukamoto, S., Mavrogenis, A.F., Akahane, M., Honoki, K., Kido, A., Tanaka, Y., Donati, D.M.,Errani, C., 2022. Risk factors of fracture following curettage for bone giant cell tumors of the extremities. BMC Musculoskelet Disord. 23, 477.

Tsukamoto, S., Mavrogenis, A.F., Tanzi, P., Leone, G., Righi, A., Akahane, M., Kido, A., Honoki, K., Tanaka, Y., Donati, D.M., et al., 2019. Similar local recurrence but better function with curettage versus resection for bone giant cell tumor and pathological fracture at presentation. J. Surg. Oncol. 119, 864-872.

Tsukamoto, S., Tanaka, Y., Mavrogenis, A.F., Kido, A., Kawaguchi, M.,Errani, C., 2020a. Is treatment with denosumab associated with local recurrence in patients with giant cell tumor of bone treated with curettage? A systematic review. Clin. Orthop. Relat. Res. 478, 1076-1085.

Tsukamoto, S., Tanaka, Y., Mavrogenis, A.F., Kido, A., Kawaguchi, M.,Errani, C., 2020b. Is treatment with denosumab associated with local recurrence in patients with giant cell tumor of bone treated with curettage? A systematic review. Clin Orthop Relat Res 478, 1076-1085.

van der Heijden, L., Dijkstra, S., van de Sande, M.,Gelderblom, H., 2020. Current concepts in the treatment of giant cell tumour of bone. Curr. Opin. Oncol. 32, 332-338.

van IJzendoorn, D.G.P., Matusiak, M., Charville, G.W., Spierenburg, G., Varma, S., Colburg, D.R.C., van de Sande, M.A.J., van Langevelde, K., Mohler, D.G., Ganjoo, K.N., et al., 2022. Interactions in CSF1-driven tenosynovial giant cell tumors. Clin Cancer Res. 28, 4934-4946.

Vari, S., Riva, F., Onesti, C.E., Cosimati, A., Renna, D., Biagini, R., Baldi, J., Zoccali, C., Anelli, V., Annovazzi, A., et al., 2022. Malignant transformation of giant cell tumour of bone: A review of literature and the experience of a referral centre. Int. J. Mol. Sci. 23, 10721.

Venneker, S., van Eenige, R., Kruisselbrink, A.B., Palubeckaite, I., Taliento, A.E., Briaire-de Bruijn, I.H., Hogendoorn, P.C.W., van de Sande, M.A.J., Gelderblom, H., Mei, H., et al., 2022. Histone deacetylase inhibitors as a therapeutic strategy to eliminate neoplastic "stromal" cells from giant cell tumors of bone. Cancers (Basel) 14, 4708.

Verschoor, A.J., Bovee, J., Mastboom, M.J.L., Sander Dijkstra, P.D., Van De Sande, M.A.J.,Gelderblom, H., 2018. Incidence and demographics of giant cell tumor of bone in the netherlands: First nationwide pathology registry study. Acta Orthop. 89, 570-574.

Yang, M., Wang, F., Lu, G., Cheng, M., Zhao, W.,Zou, C., 2022. Single-cell transcriptome analysis reveals T-cell exhaustion in denosumab-treated giant cell tumor of bone. Front. Immunol. 13, 934078.

Zhao, Y., Cai, Z., Tang, X., Du, Z., Yang, Y.,Guo, W., 2021. Preoperative denosumab may increase the risk of local recurrence of giant-cell tumor of bone treated with curettage: A systematic review and meta-analysis. J. Cancer 12, 508-517.

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 23
HTML全文浏览量: 12
PDF下载量: 0
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

The single cell transcriptomic landscape of recurrent giant cell tumor of bone following neoadjuvant denosumab therapy

doi: 10.1016/j.jgg.2026.03.001

通讯作者:
Wangjun Yan,E-mail:yanwj@fudan.edu.cn

Wending Huang,E-mail:orienthwd@163.com

计量

The single cell transcriptomic landscape of recurrent giant cell tumor of bone following neoadjuvant denosumab therapy

计量

目录

留言板

The single cell transcriptomic landscape of recurrent giant cell tumor of bone following neoadjuvant denosumab therapy

doi: 10.1016/j.jgg.2026.03.001

通讯作者: Wangjun Yan,E-mail:yanwj@fudan.edu.cn Wending Huang,E-mail:orienthwd@163.com

计量

出版历程

The single cell transcriptomic landscape of recurrent giant cell tumor of bone following neoadjuvant denosumab therapy

计量

出版历程

目录

通讯作者:
Wangjun Yan,E-mail:yanwj@fudan.edu.cn

Wending Huang,E-mail:orienthwd@163.com